Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
0.224
+0.004 (2.00%)
At close: Nov 20, 2024, 4:00 PM
0.220
-0.004 (-1.79%)
Pre-market: Nov 21, 2024, 7:38 AM EST
Mainz Biomed Employees
As of December 31, 2023, Mainz Biomed had 71 total employees, including 65 full-time and 6 part-time employees. The number of employees increased by 7 or 10.94% compared to the previous year.
Employees
71
Change (1Y)
7
Growth (1Y)
10.94%
Revenue / Employee
$12,918
Profits / Employee
-$316,998
Market Cap
5.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 71 | 7 | 10.94% |
| Dec 31, 2022 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cutera | 430 |
| Biomerica | 64 |
| Viracta Therapeutics | 40 |
| Organovo Holdings | 20 |
| TransCode Therapeutics | 10 |
| CNS Pharmaceuticals | 5 |
| Mangoceuticals | 3 |
| Hoth Therapeutics | 3 |
MYNZ News
- 4 weeks ago - Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version - GlobeNewsWire
- 7 weeks ago - Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - GlobeNewsWire
- 2 months ago - Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - GlobeNewsWire
- 2 months ago - Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert - GlobeNewsWire
- 4 months ago - Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience - GlobeNewsWire
- 4 months ago - Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test - GlobeNewsWire
- 5 months ago - Mainz Biomed Provides Half Year 2024 Corporate Update - GlobeNewsWire